Ceftaroline in complicated skin and skin-structure infections

References

• FDA.gov [homepage on the Internet]Maryland: Guidance for industry: Uncomplicated and complicated skin and skin structure infections: developing antimicrobial drugs for treatment [cited Jul 1998]. Available from: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3997B1_02_GFI-Diabetic%20Foot.pdfAccessed September 26, 2011
   Google Scholar
• FDA.gov [homepage on the Internet]Maryland: Guidance for industry: Acute bacterial skin and skin structure infections: developing drugs for treatment [cited Aug 2010]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071185.pdfAccessed September 26, 2011
   Google Scholar
• NathwaniDNew antibiotics for the management of complicated skin and soft tissue infections: are they any better?Int J Antimicrob Agents200934Suppl 1S24S2919560672
   PubMed Web of Science ®Google Scholar
• LiuCBayerACosgroveSEClinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children: executive summaryClin Infect Dis201152328529221217178
   PubMed Web of Science ®Google Scholar
• DiNubileMJLipskyBAComplicated infections of skin and skin structures: when the infection is more than skin deepJ Antimicrob Chemother200453Suppl 2ii37ii5015150182
   PubMedGoogle Scholar
• LeeSYKutiJLNicolauDPAntimicrobial management of complicated skin and skin structure infections in the era of emerging resistanceSurg Infect (Larchmt)20056328329516201938
   PubMedGoogle Scholar
• GrolmanDCTherapeutic applications of tigecycline in the management of complicated skin and skin structure infectionsInt J Infect Dis200711Suppl 1S7S1517603950
   PubMed Web of Science ®Google Scholar
• ReygaertWCAntibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecyclineTher Clin Risk Manag2010641943020856688
   PubMed Web of Science ®Google Scholar
• BarbourADerendorfHResistance and the management of complicated skin and skin structure infections: the role of ceftobiproleTher Clin Risk Manag2010648549520957140
   PubMed Web of Science ®Google Scholar
• CoreyGRWilcoxMHTalbotGHThyeDFriedlandDBaculikTCANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv41iv5121115454
   PubMed Web of Science ®Google Scholar
• FungHBChangJYKuczynskiSA practical guide to the treatment of complicated skin and soft tissue infectionsDrugs200363141459148012834364
   PubMed Web of Science ®Google Scholar
• GoldsteinEJCitronDMMerriamCVWarrenYTyrrellKLGesserRMGeneral microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactamClin Infect Dis200235Suppl 1S119S12512173120
   PubMed Web of Science ®Google Scholar
• GrahamDRLucastiCMalafaiaOErtapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter studyClin Infect Dis200234111460146812015692
   PubMed Web of Science ®Google Scholar
• JonesRNMendesRESaderHSCeftaroline activity against pathogens associated with complicated skin and skin structure infections: results from an international surveillance studyJ Antimicrob Chemother201065Suppl 4iv17iv3121115451
   PubMed Web of Science ®Google Scholar
• WilcoxMHCoreyGRTalbotGHThyeDFriedlandDBaculikTCANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv53iv6521115455
   PubMed Web of Science ®Google Scholar
• MoranGJKrishnadasanAGorwitzRJMethicillin-resistant S. aureus infections among patients in the emergency departmentN Engl J Med2006355766667416914702
   PubMed Web of Science ®Google Scholar
• SteinGEWellsEMThe importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolidCurr Med Res Opin201026357158820055750
   PubMed Web of Science ®Google Scholar
• KingMDHumphreyBJWangYFKourbatovaEVRaySMBlumbergHMEmergence of community-acquired methicillin-resistant Staphylococcus aureus USA300 clone as the predominant cause of skin and soft-tissue infectionsAnn Intern Med2006144530931716520471
   PubMed Web of Science ®Google Scholar
• SuzukiAntimicrobial ointments and methicillin-resistant Staphylococcus aureus USA300Emerg Infect Dis201117101917192022000371
   PubMed Web of Science ®Google Scholar
• MicekSTHobanAPPhamVDohertyJAKollefMHInstitutional perspective on the impact of positive blood cultures on the economic and clinical outcomes of patients with complicated skin and skin structure infections: Focus on Gram-positive infectionsClin Ther201133111759176822001358
   PubMed Web of Science ®Google Scholar
• HatoumHTAkhrasKSLinSJThe attributable clinical and economic burden of skin and skin structure infections in hospitalized patients: a matched cohort studyDiagn Microbiol Infect Dis200964330531019501792
   PubMed Web of Science ®Google Scholar
• EdelsbergJBergerAWeberDJMallickRKuznikAOsterGClinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infectionsInfect Control Hosp Epidemiol200829216016918179372
   PubMed Web of Science ®Google Scholar
• MendozaNTyringSKEmerging drugs for complicated skin and skin-structure infectionsExpert Opin Emerg Drugs201015350952020557269
   PubMed Web of Science ®Google Scholar
• NapolitanoLMEarly appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureusSurg Infect (Larchmt)20089Suppl 1s17s2718844471
   PubMed Web of Science ®Google Scholar
• GraysonMLThe treatment triangle for staphylococcal infectionsN Engl J Med2006355772472716914709
   PubMed Web of Science ®Google Scholar
• CulosKACannonJPGrimSAAlternative agents to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infectionsAm J Ther1017201145Suppl 3S184190
   Google Scholar
• MoelleringRCJrThe problem of complicated skin and skin structure infections: the need for new agentsJ Antimicrob Chemother201065Suppl 4iv3iv821115452
   PubMed Web of Science ®Google Scholar
• RaghavanMLindenPKNewer treatment options for skin and soft tissue infectionsDrugs200464151621164215257625
   PubMed Web of Science ®Google Scholar
• KrausCNBurnsteadBWThe safety record of fusidic acid in non-US markets: a focus on skin infectionsClin Infect Dis201152Suppl 7S527S53721546630
   PubMed Web of Science ®Google Scholar
• CraftJCMoriartySRClarkKA randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infectionsClin Infect Dis201152Suppl 7S520S52621546629
   PubMed Web of Science ®Google Scholar
• CercenadoEUpdate of antimicrobial resistance in Gram-positive microorganismsMed Clin (Barc)2010135Suppl 3101521477699
   PubMedGoogle Scholar
• MeraRMSuayaJAAmrine-MadsenHIncreasing role of Staphylococcus aureus and community-acquired methicillinresistant Staphylococcus aureus infections in the United States: a 10-year trend of replacement and expansionMicrob Drug Resist201117232132821417776
   PubMed Web of Science ®Google Scholar
• NicholKAAdamHJHussainZComparison of community-associated and health care-associated methicillin-resistant Staphylococcus aureus in Canada: results of the CANWARD 2007–2009 studyDiagn Microbiol Infect Dis201169332032521353960
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance SystemNational Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004Am J Infect Control200432847048515573054
   PubMed Web of Science ®Google Scholar
• TattevinPDiepBAJulaMPerdreau-RemingtonFMethicillin-resistant Staphylococcus aureus USA300 clone in long-term care facilityEmerg Infect Dis200915695395519523301
   PubMed Web of Science ®Google Scholar
• CrumNFLeeRUThorntonSAFifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureusAm J Med20061191194395117071162
   PubMed Web of Science ®Google Scholar
• KrziwanekKMetz-GercekSMittermayerHTrends in the occurrence of MRSA strains in Upper Austria from 2006 to 2009Clin Microbiol Infect201117692092321426438
   PubMed Web of Science ®Google Scholar
• ElstonJWBarlowGDCommunity-associated MRSA in the United KingdomJ Infect200959314915519619897
   PubMed Web of Science ®Google Scholar
• GoudRGuptaSNeogiUCommunity prevalence of methicillin and vancomycin resistant Staphylococcus aureus in and around Bangalore, southern IndiaRev Soc Bras Med Trop201144330931221901873
   PubMed Web of Science ®Google Scholar
• CDC.gov [homepage on the Internet]AtlantaMRSA Infections [Updated April 8, 2011] Available from: http://www.cdc.gov/mrsa/statistics/index.htmlAccessed September 29, 2011
   Google Scholar
• SaderHSJonesRNAntimicrobial susceptibility of Gram-positive bacteria isolated from US medical centers: results of the Daptomycin Surveillance Program (2007–2008)Diagn Microbiol Infect Dis200965215816219748426
   PubMed Web of Science ®Google Scholar
• NailorMDSobelJDAntibiotics for Gram-positive bacterial infection: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, telavancin, and ceftarolineMed Clin North Am2011954723742vii21679789
   PubMed Web of Science ®Google Scholar
• SaderHSFarrellDJJonesRNAntimicrobial susceptibility of Gram-positive cocci isolated from skin and skin-structure infections in European medical centresInt J Antimicrob Agents2010361283220444576
   PubMed Web of Science ®Google Scholar
• Van HalSJPatersonDLSystematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolatesAntimicrob Agents Chemother201155140541021078939
   PubMed Web of Science ®Google Scholar
• FDA.gov [homepage on the internet]MarylandTeflaro label and approval history [Updated daily, cited Nov 2010]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/200237s001lbl.pdfAccessed September 30, 2011
   Google Scholar
• FenollAAguilarLRobledoOIn vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaximeAntimicrob Agents Chemother200852114209421018725443
   PubMed Web of Science ®Google Scholar
• GeYBiekDTalbotGHSahmDFIn vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United StatesAntimicrob Agents Chemother20085293398340718625769
   PubMed Web of Science ®Google Scholar
• JacquelineCCaillonJLe MabecqueVIn vivo activity of a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, ceftaroline, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycinAntimicrob Agents Chemother200953125300530219752276
   PubMed Web of Science ®Google Scholar
• JacquelineCCaillonJLe MabecqueVIn vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis modelAntimicrob Agents Chemother20075193397340017591849
   PubMed Web of Science ®Google Scholar
• McGeeLBiekDGeYIn vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniaeAntimicrob Agents Chemother200953255255619015339
   PubMed Web of Science ®Google Scholar
• MorrisseyIGeYJanesRActivity of the new cephalosporin ceftaroline against bacteraemia isolates from patients with community-acquired pneumoniaInt J Antimicrob Agents200933651551919203863
   PubMed Web of Science ®Google Scholar
• MushtaqSWarnerMGeYKanigaKLivermoreDMIn vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypesJ Antimicrob Chemother200760230031117548456
   PubMed Web of Science ®Google Scholar
• SaderHSFritscheTRJonesRNAntimicrobial activities of ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureusAntimicrob Agents Chemother20085231153115518180353
   PubMed Web of Science ®Google Scholar
• TalbotGHThyeDDasAGeYPhase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infectionsAntimicrob Agents Chemother200751103612361617682094
   PubMed Web of Science ®Google Scholar
• VidaillacCLeonardSNSaderHSJonesRNRybakMJIn vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosaAntimicrob Agents Chemother20095362360236619349512
   PubMed Web of Science ®Google Scholar
• CoreyGRWilcoxMTalbotGHIntegrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infectionClin Infect Dis201051664165020695801
   PubMed Web of Science ®Google Scholar
• CorradoMLIntegrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infectionsJ Antimicrob Chemother201065Suppl 4iv67iv7121115456
   PubMed Web of Science ®Google Scholar
• BeckwithMCVuJNew Drug Bulletin: Ceftaroline Fosamil (Teflaro^TM-Forest Pharmaceuticals)Salt Lake CityUniversity of Utah Hospitals and Clinics2011
   Google Scholar
• KaushikDRathiSJainACeftaroline: a comprehensive updateInt J Antimicrob Agents201137538939521420284
   PubMed Web of Science ®Google Scholar
• SaravolatzLDSteinGEJohnsonLBCeftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureusClin Infect Dis20115291156116321467022
   PubMed Web of Science ®Google Scholar
• DrusanoGLPharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activityJ Antimicrob Chemother201065Suppl 4iv33iv3921115453
   PubMed Web of Science ®Google Scholar
• ZhanelGGSniezekGSchweizerFCeftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureusDrugs200969780983119441869
   PubMed Web of Science ®Google Scholar
• LimLSuttonEBrownJCeftaroline: a new broad-spectrum cephalosporinAm J Health Syst Pharm201168649149821378297
   PubMed Web of Science ®Google Scholar
• Teflaro.com [homepage on the Internet]St Louis: Teflaro: proven effective in acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. Highlights of prescribing information [Updated Apr 2011] Available from: http://www.frx.com/pi/teflaro_pi.pdfAccessed September 30, 2011
   Google Scholar
• SteedMERybakMJCeftaroline: a new cephalosporin with activity against resistant gram-positive pathogensPharmacotherapy201030437538920334458
   PubMed Web of Science ®Google Scholar
• RiccobeneTFangEThyeDA single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of ceftaroline (CPT) administered by intramuscular (IM) injection to healthy subjects [abstract no A-1888]Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy/46th Infectious Diseases Society of AmericaOctober 25–28, 2008Washington, DC
   Google Scholar
• GeYThyeDLiaoSTalbotGHPharmacokinetics (PK) of ceftaroline (PPI0903) in subjects with mild or moderate renal impairment (RI) [abstract no A-1939]Proceedings of the 46th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 27–30, 2006San Francisco, CA
   Google Scholar
• RiccobeneTJakateARankDThyeDAAn open-label, pharmacokinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysisPoster presentation at the European congress of clinical microbiology and infectious diseasesHelsinki, FinlandMay 16–19, 2009
   Google Scholar
• AndesDCraigWAPharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic targetAntimicrob Agents Chemother20065041376138316569855
   PubMed Web of Science ®Google Scholar
• LevinsonWMedical Microbiology and Immunology10th edSan Francisco, CAMcGraw-Hill2008
   Google Scholar
• VidaillacCLeonardSNRybakMJIn vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber modelAntimicrob Agents Chemother200953114712471719738009
   PubMed Web of Science ®Google Scholar
• LodiseTPLomaestroBGravesJDrusanoGLLarger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicityAntimicrob Agents Chemother20085241330133618227177
   PubMed Web of Science ®Google Scholar
• PolkREHealyDPSchwartzLBRockDTGarsonMLRollerKVancomycin and the red-man syndrome: pharmacodynamics of histamine releaseJ Infect Dis198815735025072449506
   PubMed Web of Science ®Google Scholar
• PowellJPWenzelRPAntibiotic options for treating community-acquired MRSAExpert Rev Anti Infect Ther20086329930718588495
   PubMed Web of Science ®Google Scholar
• ArbeitRDMakiDTallyFPCampanaroEEisensteinBIThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infectionsClin Infect Dis200438121673168115227611
   PubMed Web of Science ®Google Scholar
• RubinsteinELalaniTCoreyGRTelavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogensClin Infect Dis2011521314021148517
   PubMed Web of Science ®Google Scholar
• Ellis-GrosseEJBabinchakTDartoisNRoseGLohEThe efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonamClin Infect Dis200541Suppl 5S341S35316080072
   PubMed Web of Science ®Google Scholar
• Tygacil [homepage on the Internet]New York: Expanded broad-specrum IV antibiotic indicated for adults with cSSSI, cIAI, and CABP due to the indicated pathogens Available from: http://www.pfizerpro.com/hcp/tygacil/indications/cSSSIAccessed October 5, 2011
   Google Scholar
• BiekDCritchleyIARiccobeneTAThyeDACeftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activityJ Antimicrob Chemother201065Suppl 4iv9iv1621115457
   PubMed Web of Science ®Google Scholar
• BrownSDTraczewskiMMIn vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testingAntimicrob Agents Chemother20095331271127419114671
   PubMed Web of Science ®Google Scholar
• SaderHSFritscheTRKanigaKGeYJonesRNAntimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strainsAntimicrob Agents Chemother20054983501351216048970
   PubMed Web of Science ®Google Scholar